secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001437749-23-017924
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics reports positive GLP tox study for SAB-142; IND submission planned
--------------------------------------------------------------------------------

- SAB-142 well tolerated in GLP tox study; NOAEL 10 mg/kg (highest dose).
- SAB-142 modulates key T-cell subsets similarly to rabbit ATG in vivo, confirming mechanism.
- Plans to submit IND for SAB-142 to FDA and initiate Phase 1 trial in coming months.
- Over 8.4M people affected by T1D worldwide; only one disease-modifying treatment available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923017924/0001437749-23-017924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923017924/sabs20230619_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-017924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer